Sponsor study identifier
observational
0
0 countries
N/A
Study Start
November 1, 2017
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
March 2019
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
March 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The skeletal system is one of the most common sites for metastatic spread of many malignancies. Metastatic bone disease (MBD) can be associated with a significant reduction in quality of life due to debilitating pain and pathologic fractures. Multiple providers are involved in treating patients with MBD which can result in fragmented and delayed delivery of care. This fragmentation also leads to poor outcomes and patient experience. This project will assess whether it is feasible to integrate a multidisciplinary Rapid Access Metastatic Bone Disease Program (RAMP) at the Investigator's institution to improve the delivery of care to patients presenting with pelvic and lower extremity MBD. The goals of RAMP are: 1) Improve outcome and quality of care provided to MBD patients. 2) Improve patients experience through the participant's treatment journey. 3) Avert extra health care costs caused by unplanned admissions through ER and decrease redundancies due to unnecessary multiple clinic visits and double-ordering of diagnostic tests. This project will be designed to optimize the use of existing clinic resources more efficiently. Cancer patients and their loved ones will be actively engaged in the design of this project to better achieve its goals.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
December 21, 2016
Actual (reported)May 1, 2017
Actual (reported)November 1, 2017
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
March 2019
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
March 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Standardization of the referral pathways
Identifying the rate of compliance from the ER, oncology (Medical, radiation and hematology), as well as primary physicians in directing referrals to RAMP. The goal is a compliance rate of 80%. This will be measured by capturing the consults for MBD of the pelvis and lower extremity that were referred outside RAMP referral pathway.
2 years
Feasibility to triage MBD patients in currently existing musculoskeletal oncology clinics
2 years
Improve patient flow and timely access to care.
2 years
Improvement in symptom management and patient satisfaction
2 years
Improvement in counseling MBD patients about mobility aids and fall risk assessment.
2 years
No Intervention is required for this study
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Patients who are referred and subsequently followed for a diagnosis of Bone Metastatic Disease of the pelvis or lower extremities arising from a Primary Cancer elsewhere.
Hesham Abdelbary, MD
OHRI
0 participants (actual enrollment reported by the registry).
First Submitted
December 21, 2016
First Posted
May 1, 2017
Study Start
November 1, 2017
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
A Study To Observe Treatment Patterns and Outcomes in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
Contact the study team to confirm eligibility.
Primary Completion
March 2019
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
March 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
August 6, 2020
Record last verified: 2020-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: